-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
(1R)-Tenofovir-amibufenamide
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1571076-15-7.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 1571076-15-7 |
| Description | (1R)-Tenofovir amibufenamide ((1R)-HS-10234) is the isomer of Tenofovir amibufenamide, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study. |
Product Information
| Synonyms | (1R)-Tenofovir amibufenamide|HY-137453B |
| Molecular Weight | 490.49 |
| Molecular Formula | C22H31N6O5S |
| Purity | ≥98% (HPLC) |
| Solubility | In Vitro:DMSO : 200 mg/mL (407.76 mM; Need ultrasonic) |
| Appearance | Light brown to brown (Oil) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Target | HBV; HIV |
